Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

INTRODUCTION: Gefitinib (Iressa, ZD 1839, AstraZeneca) blocks the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and inhibits proliferation of several human cancer cell types including breast cancer. Phase II clinical trials with gefitinib monotherapy showed an objective res...

Descripción completa

Detalles Bibliográficos
Autores principales: Camirand, Anne, Zakikhani, Mahvash, Young, Fiona, Pollak, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175059/
https://www.ncbi.nlm.nih.gov/pubmed/15987464
http://dx.doi.org/10.1186/bcr1028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175059/
https://www.ncbi.nlm.nih.gov/pubmed/15987464
http://dx.doi.org/10.1186/bcr1028

Ejemplares similares